A Proposed Community Pharmacy-Led Multi-Condition Screening and Referral Protocol for Urban Lagos, Nigeria: Development, Data Model, and Synthetic Demonstration Dataset

This record contains a protocol development manuscript and an accompanying synthetic demonstration dataset. The manuscript describes the development of a one-day community screening and referral protocol that a community pharmacy could use in a dense urban neighbourhood, comprising an opening group briefing and health talk followed by six stations: registration and anthropometry; asthma symptom screen with the Asthma Control Test (ACT, age 12 and over) or Childhood ACT (C-ACT, age 8 to 11); seated blood pressure measurement (age 18 and over); capillary glucose screening (age 25 and over); a visual oral health check; and a closing education and referral station. Referral decisions use the Nigerian Federal Ministry of Health hypertension grades (2023-2028) with ACC/AHA categories retained for analysis; glucose values are screening flags per American Diabetes Association cut-points, with hypoglycaemia classified by ADA level (level 1, level 2, level 3 as an event); asthma symptom control uses the ACT/C-ACT and is not diagnostic; oral findings are a screening inspection. A 71-field participant-level data model and a linked 13-field operational referral register with row-level data dictionaries, a four-tier referral pathway (emergency, same-day, within two weeks, none), a guideline-to-protocol mapping table, an ethics and governance section, and a provisional evaluation framework are specified. The protocol was developed from the author's experience and operational documentation of community outreach activities conducted through AB-Medz Nigeria Limited, a registered community pharmacy in Lagos, in the Ketu, Ikosi, and Alapere neighbourhoods of Kosofe Local Government Area, with outreach forming part of a Federal Government of Nigeria YOUWIN! enterprise grant (2014). Registers from those activities were anonymised paper logs and are not available for analysis; the manuscript reports no attendance, yield, or outcome data and is not an evaluation of them. IMPORTANT: All data in this record are synthetic. The demonstration dataset contains 300 generated participant records and no real participants; no participants were enrolled for the manuscript and no real screening data were analysed. Abnormal findings were deliberately over-represented so that every branch of the referral logic appears in the data. Its values are not prevalence estimates and must not be cited as findings of any real screening activity. The file is provided so that implementers can build and test data capture and reporting pipelines before enrolling participants. Version 2.4 was generated by the deposited Python script (seed 20260909; fixed neighbourhood quotas 120/85/95); a separately implemented, author-conducted validation script (84 checks) and 97 hand-specified boundary-case tests both pass; together they exercise every deterministic referral branch (recovery at cycle 3 is exercised in the boundary suite only). It contains a participant file (300 records, 71 fields), a linked referral register (548 rows, 13 fields), data dictionaries, a change log, and the reports. Clinical rules are aligned with GINA 2026, the 2025 AHA/ACC hypertension guideline, the ADA 2026 Standards of Care, and the Nigerian FMOH hypertension guideline 2023-2028. The protocol is PROPOSED and requires multidisciplinary clinical review and ethics approval before use. Superseded versions are not in this record; version 1.0 is archived separately as a teaching artefact. Author: Adesola Olubanke Akin-Fadele, B.Pharm., MBA (Midwest Prohealth, Rochester, Minnesota, USA; formerly Founder and Pharmaceutical Director, AB-Medz Nigeria Limited, Lagos). Sole author. No external funding supported preparation of the manuscript. The manuscript analyses no real participant data. Ethics: no ethics committee approval was sought because no participants were enrolled and no real data were used; the demonstration dataset is computer-generated. Version 1 (September 2026): manuscript prepared for journal submission after eight rounds of editorial and AI-assisted critique; synthetic demonstration dataset v2.4 generated from the deposited seeded script; author-conducted internal validation (84 checks) and boundary tests (97 cases) pass. The protocol is proposed; multidisciplinary clinical review is sought. No ethics committee approval was sought because no participants were enrolled and no real data were used. The dataset is synthetic and reports no real participant data. Competing interests: the author is employed by GSK as a Specialty Account Specialist; the manuscript was prepared independently and GSK had no role in it; the ACT and C-ACT are referenced and scored but not reproduced (the C-ACT carries a GSK copyright). The author designed the protocol, founded and directed AB-Medz Nigeria Limited, and is Founder and Executive Director of Midwest Prohealth, which applies similar design principles in a different setting.